Ad
related to: moderna
Search results
Moderna (NASDAQ:MRNA) Upgraded to Hold by Evercore ISI
ETF DAILY NEWS· 10 hours agoEvercore ISI upgraded shares of Moderna (NASDAQ:MRNA – Free Report) to a hold rating in a research note released on Monday, Zacks.com reports. Canaccord Genuity Group lifted ...
Moderna director Noubar Afeyan sells over $1.8m in company stock By Investing.com
Investing.com· 6 days agoModerna , Inc. (NASDAQ:MRNA) director Noubar Afeyan has recently sold a significant amount of...
Is This a Setback for Moderna?
The Motley Fool via AOL· 2 days agoInvestors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it...
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
Zacks via Yahoo Finance· 3 days agoModerna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is...
Smart Money Is Betting Big In MRNA Options - Moderna (NASDAQ:MRNA)
Benzinga· 23 hours agoLoading... Loading... Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna . Looking at options history for Moderna MRNA ...
Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?
Motley Fool via Yahoo Finance· 4 days agoModerna (NASDAQ: MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every...
Cramer's Lightning Round: 'I'm a believer' in Moderna
CNBC· 2 days ago"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to...
Jim Cramer: This Industrial Company Is ‘Absolutely Terrific’, Recommends Buying Modine Manufacturing...
Benzinga· 1 day agoOn CNBC's “Mad Money Lightning Round,” Jim Cramer believes in Moderna, Inc. On May 14, Evercore ISI Group analyst Cory Kasimov initiated coverage on Moderna
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 2 days agoModerna stock tumbled — and then rebounded — after the Food and Drug Administration delayed its RSV...
FDA delays decision on Moderna RSV vaccine
BioPharma Dive via Yahoo Finance· 6 days agoThe regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.